OPTIMIZING NASAL FOROPTIMIZING NASAL FORMULATION FOR PREVENTION OF SERIOUS INFECTIONS CAUSED BY MRSAMULATION FOR PREVENTION OF SERIOUS INFECTIONS CAUSED BY MRSA
Keywords:
MRSA, Nasal inserts, Nasal dosage form, Lyophilization, Bioadhesion, Mupirocin, MethylcelluloseAbstract
Objective: Lyophilized nasal insert formulations containing 2% mupirocin which is an antibiotic used to prevent serious infections caused by meticillin resistant Staphylococcus aureus (MRSA) pathogen were prepared.
Methods: Different grades of methylcellulose (MC) polymerwere used to prepare mupirocin nasal inserts using aqueous (water) and organic (tertiary butyl alcohol) methods. Dynamic adhesion, drug release profile and antibiotic sensitivity studies were undertaken to evaluate the performance of the nasal inserts in comparison to Bactroban nasal ointment.
Results: The results showed that each grade of MC polymer has different adhesion properties. In organic prepared formulations,the solution form of mupirocin in tertiary butyl alcohol resulted in a significant increase in the adhesion of these formulations in comparison with blank formulations. On the other hand, mupirocin suspended in aqueous solvent (water) had little effect. However both aqueous and organic prepared formulations resulted higher adhesion performance when compared to Bactroban nasal ointment. The drug release of incorporated mupirocin from MC matrix of organic prepared formulations after 180 minuteswas slower (11.9-12.5%) than mupirocin from aqueous prepared formulations (85.6-88.4%). while, the maximum percent of mupirocin releasedfrom Bactroban nasal ointment was just 4% after the same time.
Conclusion: The growth inhibition of Staphylococcus aureus pathogen obtained by using lyophilized nasal insert formulationwhich contained Mupirocin was very active. Thus, the nasal insert is promising in treatment of nasal colonizedby MRSA.
Â
Downloads
References
Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: physicochemical and therapeutic aspects. Int J Pharm 2007;337:1-24.
Leonard AK, Sileno AP, Brandt GC, Foerder CA, Quay SC, Costantino HR. In vitro formulation optimization of intranasal galantamine leading to enhanced bioavailability and reduced emetic response in vivo. Int J Pharm 2007;335:138-46.
Coates T, Bax R, Coates A. Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. J Antimicrobial Chem 2009;64:9-15.
Immerman I, Ramos NL, Katz GM, Hutzler LH, Phillips MS, Bosco JA. 3rd: The persistence of Staphylococcus aureus decolonization after mupirocin and topical chlorhexidine: implications for patients requiring multiple or delayed procedures. J Arthroplasty 2012;27:870-6.
Levya P-Y, Ollivierb M, Drancourta M, Raoulta D, Argenson J-N. Relation between nasal carriage of Staphylococcus aureus and surgical site infection in orthopedic surgery: The role of nasal contamination. A Syst Lit Rev Meta-Anal OTSR 2013;99:535-42.
Jones JC, Rogers TJ, Brookmeyer P, Dunne WM Jr, Storch GA, Coopersmith CM, et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. CID 2007;45:541-7.
Walker ES, Vasquez JE, Dula R, Bullock H, Sarubbi FA. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect Control Hosp Epidemiol 2003;24:342-6.
Sandri AM, Dalarosa MG, Ruschel de Alcantara L, da Silva Elias L, Zavascki AP. Reduction in incidence of nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection in an intensive care unit: role of treatment with mupirocin ointment and chlorhexidine baths for nasal carriers of MRSA. Infect Cont Hosp Ep 2006;27:185-7.
Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. Drug Discovery Today 2002;7:967-75.
Dondeti P, Zia H, Needham TE. Bioadhesive and formulation parameters affecting nasal absorption. Int J Pharm 1996;127:115-33.
Alfadhel M, Puapermpoonsiri U, Ford SJ, McInnes FJ, van der Walle CF. Lyophilized inserts for nasal administration harboring bacteriophage selective for Staphylococcus aureus: In vitro evaluation. Int J Pharm 2011;416:280-7.
McInnes FJ, O'Mahony B, Lindsay B, Band J, Wilson CG, Hodges LA, et al. Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scintigraphy. Eur J Pharm Sci 2007;31:25-31.
McInnes FJ, Thapa P, Baillie AJ, Welling PG, Watson DG, Gibson I, et al. In vivo evaluation of nicotine lyophilised nasal insert in sheep. Int J Pharm 2005;304:72-82.
LIFE I: Laboratory freeze dryers advanced processed. In IMA life freeze drying solutions, IMA Industreis IMA Pharma. New York, USA, IMA LIFE North America Inc; 20.
Shah V, Sharma M, Parmar V, Upadhyay U. Formulation of sildenafil citrate loaded nasal microsphers: an In vitro, ex vivo characterization. Int J Drug Del 2010;2:213-20.
Bertram U, Bodmeier R. In situ gelling, bioadhesive nasal inserts for extended drug delivery: In vitro characterization of a new nasal dosage form. Eur J Pharm Sci 2006;27:62-71.
McInnes F, Baillie AJ, Stevens HNE. Quantification of adhesion of lyophilised HPMC formulations using a novel dynamic adhesion test. AAPS Pharm Sci 2001;3(S1):s1708.
Patil P, Gupta V, Udupi R, Srikanth K, Prasad B. Development of dissolution medium for poorly water soluble drug mefenamic acid. RJPBCS 2010;1:544-9.
Wesseling M, Bodmeier R. Drug release from beads coated with an aqueous colloidal ethylcellulose dispersion, Aquacoat, or an organic ethylcellulose solution. Eur J Pharm Biopharm 1999;47:33-8.
Anderson NH, Bauer M, Boussac N, Khan-Malek R, Munden P, Sardaro M. An evaluation of fit factors and dissolution efficiency for the comparison of In vitro dissolution profiles. J Pharm Biomed Anal 1998;17:811-22.
Liu Q, Fassihi R. Application of a novel symmetrical shape factor to gastroretentive matrices as a measure of swelling synchronization and its impact on drug release kinetics under standard and modified dissolution conditions. J Pharm Pharmacol 2009;61:861-7.
Rowe RC, Sheskey PJ, PJW. Methylcellulose. In Handbook of Pharmaceutical Excipients. London: Pharmaceutical Press and American Pharmaceutical Association; 2003. p. 438-41.
Naruenartwongsakul S, Chinnan MS, Bhumiratana S, Yoovidhya T. Pasting characteristics of wheat flour-based batters containing cellulose ethers. LWT-Food Sci Technol 2004;37:489-95.
Lee JW, Park JH, Robinson JR. Bioadhesive-based dosage forms: the next generation. J Pharm Sci 2000;89:850-66.
Agyralides GG, Dallas PP, Rekkas DM. Development and In vitro evaluation of furosemide transdermal formulations using experimental design techniques. Int J Pharm 2004;281:35-43.
Henriksen I, Green KL, Smart JD, Smistad G, Karlsen J. Bioadhesion of hydrated chitosans: an In vitro and in vivo study. Int J Pharm 1996;145:231-40.
Elgindy N, Elkhodairy K, Molokhia A, Elzoghby A. Lyophilization monophase solution technique for improvement of the physicochemical properties of an anticancer drug, flutamide. Eur J Pharm Biopharm 2010;74:397-405.
Kalaiselvan R, Mohanta GP, Kannan K, Manna PK, Manavalan R. Optimization of drug-polymer mixing ratio in albendazole-polyvinylpyrrolidone solid dispersion by moisture absorption studies. Acta Pharm Sci 2006;48:141-51.
Viera RGP, Filho GR, De Assunc RMN, Meireles CS, Vieira JLG, De Oliveira GS. Synthesis and characterization of methylcellulose from sugar cane bagasse cellulose. Carbohydr Polym 2007;67(2):182-9.
Amjad Z. Water soluble polymers: solution properties and applications. ed illustrated, New York, London, Springer; 1998.
Raghavan SL, Kiepfer B, Davis AF, Kazarian SG, Hadgraft J. Membrane transport of hydrocortisone acetate from supersaturated solutions; the role of polymers. Int J Pharm 2001;221:95-105.
Chapman BE, Kuchel PW. NMR of solute exchange across the human erythrocyte membrane. Diff Fund 2007;4:8, 1-8, 15.
Ichinaito S, Hungtsai Y. Percutaneous absorption of indomethacin from ointment bases in rabbits. Int J Pharm 1981;8:263-76.